WO2005030225A3 - Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers - Google Patents

Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers Download PDF

Info

Publication number
WO2005030225A3
WO2005030225A3 PCT/CA2004/001697 CA2004001697W WO2005030225A3 WO 2005030225 A3 WO2005030225 A3 WO 2005030225A3 CA 2004001697 W CA2004001697 W CA 2004001697W WO 2005030225 A3 WO2005030225 A3 WO 2005030225A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting
expression
genes
drug resistance
effectiveness
Prior art date
Application number
PCT/CA2004/001697
Other languages
French (fr)
Other versions
WO2005030225A2 (en
Inventor
Kristina Sachs-Barrable
Tatjana Lukic
David John Stewart
Kishor M Wasan
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Priority to EP04761853A priority Critical patent/EP1677803A2/en
Priority to CA002540364A priority patent/CA2540364A1/en
Priority to JP2006527239A priority patent/JP2007524651A/en
Priority to BRPI0414812-6A priority patent/BRPI0414812A/en
Priority to AU2004275444A priority patent/AU2004275444A1/en
Publication of WO2005030225A2 publication Critical patent/WO2005030225A2/en
Publication of WO2005030225A3 publication Critical patent/WO2005030225A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention provides, in one aspect, a method of inhibiting the expression of a multi-drug resistance gene in an animal cell which comprises administering to an animal an effective amount of at least one cholesterol absorption inhibitor. In another aspect, it provides a method of inhibiting the production of a protein expressed by a multi-drug resistance gene in an animal cell which comprises administering to an animal an effective amount of at least one cholesterol absorption inhibitor. In another aspect, the present invention provides a method of enhancing the effectiveness of a chemotherapeutic agent in an animal having cancer, which comprises administering to said animal an effective amount of the chemotherapeutic agent and at least one cholesterol absorption inhibitor. Further, there are provided compositions and kits for use in cancer treatment which comprise at least one chemotherapeutic agent and at least one cholesterol absorption inhibitor.
PCT/CA2004/001697 2003-09-26 2004-09-27 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers WO2005030225A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04761853A EP1677803A2 (en) 2003-09-26 2004-09-27 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
CA002540364A CA2540364A1 (en) 2003-09-26 2004-09-27 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
JP2006527239A JP2007524651A (en) 2003-09-26 2004-09-27 A method of suppressing the expression of a multi-drug resistance gene to suppress the production of a protein caused by the expression of the gene, thereby increasing the effectiveness of a chemotherapeutic agent for cancer treatment.
BRPI0414812-6A BRPI0414812A (en) 2003-09-26 2004-09-27 method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancer
AU2004275444A AU2004275444A1 (en) 2003-09-26 2004-09-27 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67305103A 2003-09-26 2003-09-26
US10/673,051 2003-09-26

Publications (2)

Publication Number Publication Date
WO2005030225A2 WO2005030225A2 (en) 2005-04-07
WO2005030225A3 true WO2005030225A3 (en) 2005-05-26

Family

ID=34393484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/001697 WO2005030225A2 (en) 2003-09-26 2004-09-27 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers

Country Status (9)

Country Link
EP (1) EP1677803A2 (en)
JP (1) JP2007524651A (en)
KR (1) KR20060135615A (en)
CN (1) CN1874780A (en)
AU (1) AU2004275444A1 (en)
BR (1) BRPI0414812A (en)
CA (1) CA2540364A1 (en)
RU (1) RU2006114049A (en)
WO (1) WO2005030225A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635705B2 (en) 2005-06-20 2009-12-22 Schering Corporation Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
KR20160066557A (en) * 2008-03-14 2016-06-10 제넨테크, 인크. Genetic variations associated with drug resistance
CN102552284A (en) * 2011-12-13 2012-07-11 陕西师范大学 Application of ergosterol in preparation of tumor multidrug resistance reversing medicines
AU2015222917A1 (en) 2014-02-27 2016-09-15 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
AU2016257997A1 (en) 2015-05-05 2017-11-09 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
JP6838004B2 (en) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ Aryldihydro-2H-benzo [b] [1,4] oxazine sulfonamides and related compounds for use as agonists of RORγ and for the treatment of diseases
CN106420768B (en) * 2015-08-13 2018-12-28 广州中医药大学第二附属医院 Application of the Cheng ketone sterol as P- glycoprotein inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017192A1 (en) * 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
US20030130296A1 (en) * 2001-08-13 2003-07-10 Ulrike Bauer FXR NR1H4 nuclear receptor binding compounds
US20040116358A1 (en) * 2002-07-30 2004-06-17 Schaffner Carl P. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017192A1 (en) * 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
US20030130296A1 (en) * 2001-08-13 2003-07-10 Ulrike Bauer FXR NR1H4 nuclear receptor binding compounds
US20040116358A1 (en) * 2002-07-30 2004-06-17 Schaffner Carl P. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGARWAL ET AL: "Lovastatin Augments Apoptosis Induced by Chemotherapeutic Agents in Colon Cancer Cells", CLINICAL CANCER RESEARCH, vol. 5, August 1999 (1999-08-01), pages 2223 - 2229, XP009183462 *
KOZUBEK ET AL: "Liposomal Drug Delivery, A Novel Approach: PLARosomes", ACTA BIOCHIMICA POLONIA, REVIEW, vol. 47, no. 3, 2000, pages 639 - 649, XP002981870 *
METHERALL ET AL: "Role of multidrug Resistance P-glycoproteins in Cholesterol Biosynthesis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 5, February 1996 (1996-02-01), pages 2634 - 2640, XP002937752, DOI: doi:10.1074/jbc.271.5.2634 *
RAMSWAMY ET AL: "Influence of Phytostanol Phosphoryl Ascorbate, FM-VP4, on Pancreatic Lipase Activity and Cholesterol Accumulation within Caco-2 Cells", JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCE, vol. 5, no. 1, 2002, pages 29 - 38 *

Also Published As

Publication number Publication date
KR20060135615A (en) 2006-12-29
JP2007524651A (en) 2007-08-30
BRPI0414812A (en) 2006-11-14
CN1874780A (en) 2006-12-06
CA2540364A1 (en) 2005-04-07
RU2006114049A (en) 2007-11-20
WO2005030225A2 (en) 2005-04-07
AU2004275444A1 (en) 2005-04-07
EP1677803A2 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
WO2005030121A3 (en) Compounds, compositions and methods
WO2004085418A3 (en) Xanthones, thioxanthones and acridinones as dna-pk inhibitors
WO2004048551A3 (en) Target for therapy of cognitive impairment
WO2005004794A8 (en) Method of treating neurodegenerative disease
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2007087451A3 (en) Compositions and methods for enhancing discriminatory rna interference
WO2003064625A3 (en) Oligonucleotide compositions with enhanced efficiency
WO2005047477A3 (en) Interspersed repetitive element rnas as substrates, inhibitors and delivery vehicles for rnai
WO2007011962A3 (en) Treatment of cancer
WO2006020768A3 (en) Chemically modified oligonucleotides
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
WO2005042692A3 (en) A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2007009191A8 (en) Method for treating cancer
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
HK1091127A1 (en) Compounds and methods for downregulating the effects of tgf-beta
WO2004017948A8 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
WO2009027978A8 (en) NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2005030225A3 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
EP2357235A3 (en) Compositions and methods for therapy and diagnosis of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480031697.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 546161

Country of ref document: NZ

Ref document number: 2006527239

Country of ref document: JP

Ref document number: 1020067005929

Country of ref document: KR

Ref document number: 2004275444

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2540364

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004275444

Country of ref document: AU

Date of ref document: 20040927

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004275444

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004761853

Country of ref document: EP

Ref document number: 2006114049

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004761853

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0414812

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020067005929

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2004761853

Country of ref document: EP